Accordingly, pharmacological inhibition of the PPIase activity by SAFit2 treatment affects PDL-1 glycosylation, plasma membrane expression, and contrasts PDL-1-induced cell death of activated lymphocytes cocultured with glioblastoma cells [73,79]. The gene discussed is FKBP5; the disease is glioblastoma.